First Report Customer Care 
All time: 4.6

Latest / Last 30 Days: 5.0

521 Reviews

Credit Rating - MEDIMMUNE LIMITED

ANALYSIS
Credit Risk Update: SECURED CREDITOR INFORMATION: MEDIMMUNE LIMITED, 1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE, CB2 0AA. The legal status is a Private Limited Company and the current status at the registry of companies is Active. The last filed accounts are dated 31 December 2022. The company was incorporated on 11 December 1989.

The accounts next due date is 30 September 2024. There are 5 mortgages, none satisfied, none part satisfied and 5 unsatisfied.

The above was based on public record information as at 17 April 2024 and may not reflect the current status. Please access the current report to ascertain the current status and credit rating.
SUMMARY
Registered Number: 02451177
Date Incorporated: 11 December 1989
Date Latest Accounts: 31 December 2022
BUSINESS INFORMATION
Legal Form: Private Limited Company
Previous Names: CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED
Registered Number: 02451177
Annual Return: 11 December 2015
Registered Office: 1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE, CB2 0AA
SIC Code and Operations: 72190
SECURED CREDITORS
Number of Mortgages 5
Satisfied Mortgages 0
Part Satisfied Mortgages 0
Unsatisfied Mortgages 5
CREDIT RISK RATING
This is the credit risk assessment used by one of the top UK credit reference agencies.
Risk Score (1-100):

MEDIMMUNE LIMITED

Click Here

to view this information

Risk Assessment:
Credit Rating:



First Report Score: (0-10):

Financial Status Guide:
10  trafficlight Very Strong
9   Strong
8 Very Good
7 Good
6 Above Average
5 Average
4 Below Average
3 Poor
2 Weak
1 Very Weak
0 Critical
Report Created On 27 April 2024 Copyright © 2024 First Report Ltd


Recent Searches

Reg No. Reg Name Status
03854275 MEDIMMUNE U.K. LIMITED Active
09155001 MEDIMOAT LTD Active - Proposal to Strike off
14224012 MEDIMOB LTD Active
12532039 MEDIMOD LIMITED Active
12057193 MEDIMOG LTD Active

In using this service you agree to the Terms and Conditions

© 2024 First Report Ltd